Illuminating Alternative Strategies to Treat Targeted Chemotherapy-Resistant Sporadic Basal Cell Carcinoma

Tuyen T L Nguyen; Scott X Atwood

doi:10.1016/j.jid.2017.11.013

Illuminating Alternative Strategies to Treat Targeted Chemotherapy-Resistant Sporadic Basal Cell Carcinoma

J Invest Dermatol. 2018 May;138(5):1017-1019. doi: 10.1016/j.jid.2017.11.013.

Authors

Tuyen T L Nguyen¹, Scott X Atwood²

Affiliations

¹ Department of Developmental and Cell Biology, University of California, Irvine, California, USA.
² Department of Developmental and Cell Biology, University of California, Irvine, California, USA; Department of Dermatology, University of California, Irvine, California, USA; Chao Family Comprehensive Cancer Center, University of California, Irvine, California, USA. Electronic address: [email protected].

PMID: 29681387
DOI: 10.1016/j.jid.2017.11.013

Abstract

Sporadic and basal cell nevus syndrome basal cell carcinomas show differential response rates to Smoothened inhibitors. Chiang et al. demonstrate notable decreases in UV-induced mutagenesis, total mutation load, genomic instability, and drug-resistant mutations among basal cell nevus syndrome basal cell carcinomas using whole exome sequencing, which may explain the differences in drug response rates.

Publication types

Comment

MeSH terms

Basal Cell Nevus Syndrome*
Carcinoma, Basal Cell*
Genomic Instability
Humans
Mutation
Skin Neoplasms*